Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acasti Pharma (ACST)

Acasti Pharma (ACST)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,931
  • Shares Outstanding, K 91,530
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,510 K
  • 60-Month Beta 2.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.28
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.27
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/12/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.07
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6000 +18.23%
on 07/30/20
0.8300 -14.53%
on 08/03/20
+0.0382 (+5.69%)
since 07/14/20
3-Month
0.4400 +61.23%
on 06/30/20
0.9600 -26.10%
on 06/03/20
+0.0916 (+14.83%)
since 05/14/20
52-Week
0.2500 +183.76%
on 03/19/20
3.0800 -76.97%
on 12/23/19
-1.3406 (-65.40%)
since 08/14/19

Most Recent Stories

More News
What Makes Acasti (ACST) a New Buy Stock

Acasti (ACST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ACST : 0.7094 (-6.65%)
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST : 0.7094 (-6.65%)
ACST.VN : 0.930 (-7.00%)
Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020

Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre(R)...

ACST : 0.7094 (-6.65%)
ACST.VN : 0.930 (-7.00%)
FDA Advisory Committee Recommends Mallinckrodt's Trelipressin

The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.

EBS : 133.42 (-1.13%)
ACST : 0.7094 (-6.65%)
MNK : 1.6500 (+1.23%)
PSNL : 20.17 (+1.46%)
Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.7094 (-6.65%)
ACST.VN : 0.930 (-7.00%)
Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA

FDA response expected on or before June 30, 2020

ACST : 0.7094 (-6.65%)
ACST.VN : 0.930 (-7.00%)
Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.7094 (-6.65%)
ACST.VN : 0.930 (-7.00%)
Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.7094 (-6.65%)
ACST.VN : 0.930 (-7.00%)
Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico

Patent upheld in Japan following opposition filings and subsequently allowed

ACST : 0.7094 (-6.65%)
ACST.VN : 0.930 (-7.00%)
Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements

Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST - TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate...

ACST : 0.7094 (-6.65%)
ACST.VN : 0.930 (-7.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ACST with:

Business Summary

Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R)...

See More

Key Turning Points

2nd Resistance Point 0.7953
1st Resistance Point 0.7524
Last Price 0.7094
1st Support Level 0.6641
2nd Support Level 0.6187

See More

52-Week High 3.0800
Fibonacci 61.8% 1.9989
Fibonacci 50% 1.6650
Fibonacci 38.2% 1.3311
Last Price 0.7094
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar